References
- Au WY, Chim CS, Lie AK, et al. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002;117:130–132.
- Au WY, Tam S, Fong BM, et al. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008;112:3587–3590.
- Au WY, Li CK, Lee V, et al. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatric Blood Cancer 2012;58:630–632.
- Au WY, Kumana CR, Lam CW, et al. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia. Leuk Res 2007;31:105–108.
- Glattre E, Mravcova A, Lener J, et al. Study of distribution and interaction of arsenic and selenium in rat thyroid. Biol Trace Elem Res 1995;49:177–186.
- Yamamoto S, Konishi Y, Matsuda T, et al. Cancer induction by an organic arsenic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res 1995;55:1271–1276.
- Chang TC, Hong MC, Chen CJ. Higher prevalence of goiter in endemic area of blackfoot disease of Taiwan. J Formos Med Assoc 1991;90:941–946.
- Yoshida T, Yamauchi H, Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol 2004;198:243–252.